Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT3 | O60678 | 14/20 | 0.49 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL567504 | 1.00 | PRMT3 (0.49) | PRMT3JAK2ROCK2ROCK1JAK3 | |
| Hydrochloric Acid SCHEMBL567467 | 0.99 | PRMT3 (0.48) | PRMT3JAK2ROCK2ROCK1JAK3 | |
| Hydrochloric Acid SCHEMBL567468 | 0.99 | PRMT3 (0.48) | PRMT3JAK2ROCK2ROCK1JAK3 | |
| SCHEMBL567154 | 0.89 | MMP1 (0.46) | PRMT3JAK2ROCK2ROCK1JAK3 | |
| SCHEMBL567155 | 0.89 | MMP1 (0.46) | PRMT3JAK2ROCK2ROCK1JAK3 | |
| Hydrochloric Acid SCHEMBL567830 | 0.88 | MMP1 (0.47) | PRMT3JAK2ROCK2ROCK1JAK3 | |
| Hydrochloric Acid SCHEMBL567829 | 0.88 | MMP1 (0.47) | PRMT3JAK2ROCK2ROCK1JAK3 | |
| SCHEMBL568035 | 0.87 | MMP1 (0.48) | PRMT3JAK2ROCK2ROCK1JAK3 | |
| SCHEMBL568036 | 0.87 | MMP1 (0.48) | PRMT3JAK2ROCK2ROCK1JAK3 | |
| SCHEMBL28637058 | 0.86 | JAK2 (0.42) | PRMT3JAK2ROCK2ROCK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. WESTERN THERAPEUTICS INSTITUTE, INC (JP) | 2012-02-09 | — | — | US | claimed |
| US-8951997-B2 | Substituted isoquinoline derivative | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. WESTERN THERAPEUTICS INSTITUTE, INC (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | SULT1A1, SULT1E1, SULT2A1 | PRMT3 237/4885JAK2 575/4885ROCK2 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.